



安徽贝克联合制药有限公司

Anhui Biochem United Pharmaceutical Co., Ltd

December 05, 2022

To:

1. Gilead Sciences, inc.
333 Lakeside Drive, Foster City
California 94404, USA

2. Medicines Patent Pool
Chemin Louis-Dunant 17
1202 Geneva, Switzerland

Sub: Termination of tenofovir alafenamide (“TAF”), tenofovir disoproxil fumarate (“TDF”), elvitegravir (“EVG”), bicitgravir (BIC) and cobicistat (“COBI”).

Ref: License Agreement dated June 22, 2017, executed by and between Gilead Sciences, Inc., The Medicines Patent Pool and Anhui Biochem United Pharmaceutical Co.,Ltd.

Dear Sir/Madam

In accordance to Section 10.5 of the above-mentioned Licence Agreement, We Anhui Biochem United Pharmaceutical Co.,Ltd provides notice of termination of the licence for tenofovir alafenamide (“TAF”), tenofovir disoproxil fumarate (“TDF”), elvitegravir (“EVG”), bicitgravir (BIC) and cobicistat (“COBI”) effective immediatedly.

We look forward to a fruitful and collaborative relationship with Gilead Science and the Medicines Patent Pool.

Yours Sincerely

Sean Wang
Vice-General Manager
Anhui Biochem United pharmaceutical Co Ltd.